SCHEMBL30731964

SCHEMBL30731964

Cn1nc(-c2ccc(OCc3ccccc3)nc2OCc2ccccc2)c2cccc(C3=C[C@@H]4CC[C@H](C3)N4C(=O)OC(C)(C)C)c21

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.34
GPR119 Q8TDV5 3/20 0.34
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
JAK1 P23458 2/20 0.31
JAK2 O60674 1/20 0.31
PKM P14618 1/20 0.31
PRMT5 O14744 2/20 0.31
WDR5 P61964 2/20 0.31
HTR1A P08908 1/20 0.31
TLR9 Q9NR96 1/20 0.31
TLR7 Q9NYK1 1/20 0.31
JAK3 P52333 1/20 0.30
SLC6A2 P23975 1/20 0.30
SLC6A4 P31645 1/20 0.30
SLC6A3 Q01959 1/20 0.30
GRM5 P41594 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26924683 0.92 HTR3A (0.36) HTR3APKMHTR1AJAK3SLC6A2
SCHEMBL26636757 0.82 PDK4 (0.46) GPR119JAK1GRM5
SCHEMBL30731761 0.81 MERTK (0.37) GPR119PKMPRMT5TLR9TLR7
SCHEMBL26924707 0.81 MERTK (0.37) GPR119PKMPRMT5TLR9TLR7
SCHEMBL26925614 0.79 MERTK (0.38) GPR119PKMPRMT5
SCHEMBL30731829 0.79 MERTK (0.38) GPR119PKMPRMT5
SCHEMBL26924348 0.79 GPR119 (0.38) HTR3AGPR119JAK1PRMT5TLR9
SCHEMBL30705924 0.79 GPR119 (0.38) HTR3AGPR119JAK1PRMT5TLR9
SCHEMBL26636825 0.77 TLR9 (0.44) GPR119TLR9TLR7
SCHEMBL30663129 0.77 PRMT5 (0.41) GPR119JAK1JAK2PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 US disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 EP disclosed
EP-4536658-A1 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 EP disclosed
CN-119317623-A Tricyclic quinolone BCL6 bifunctional degradation agents 树线生物科学公司 2025-01-14 CN disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 US disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR HTR3A 3176/4885GPR119 3864/4885PDCD1 2625/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR HTR3A 3176/4885GPR119 3864/4885PDCD1 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.